Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

Inclusion Criteria

• •Understand and voluntarily sign an informed consent form.
• •Age \> = 18 years at the time of signing the informed consent form.
• •Able to adhere to the study visit schedule and other protocol requirements.
• •Must have confirmed diagnosis of plasma cell disorder.
• •Patients with prior thalidomide or CC-5013 (lenalidomide) use are eligible but these agents must have been discontinued at least 4 weeks prior to treatment in this study.
• •All previous cancer therapy, including chemotherapy, and dexamethsone must have been discontinued at least 4 weeks prior to treatment in this study. Patients with recent radiation, hormonal therapy and surgery are eligible.
• •Patients must not have received prior Hepatitis B vaccination.
• •Patient should be negative for antibody against HbSAg.
• •ANC \>= 1000, Platelets \>= 75,000.
• •Women of childbearing potential (WCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active WCBP must agree to use two of the following adequate forms of contraception throughout the entire study (tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). A WCBP must agree to have pregnancy tests 4 weeks after her last dose of lenalidomide. Due to the short duration of drug therapy, abstinence would also be a reasonable option.